Miss Grieve completed her undergraduate medical studies at George’s Hospital Medical School in 1990. The majority of her neurosurgical training was undertaken at Atkinson Morley’s Hospital in Wimbledon, although she also spent time at the National Hospital for Neurology and Neurosurgery and Great Ormond Street Hospital for Children. She successfully passed FRCS(SN) in 2000 and was appointed consultant neurosurgeon at the National Hospital for Neurology and Neurosurgery (NHNN) in 2002.
During her training Miss Grieve undertook research at the NHNN and was awarded her MD thesis entitled ‘Novel imaging techniques in brain arteriovenous malformations’ by the University of London in 2004.
Her clinical interests include pituitary and parasellar pathologies; cavernous haemangiomas; and gamma knife radiosurgery as well as general intracranial neurosurgery.
The National Neurosurgical Audit Programme (NNAP), administered by the Society of British Neurological Surgeons (SBNS), has shown that between 2013-2015, Miss Grieve personally undertook 9% (305 operations out of a total 3300) of the total number of pituitary procedures and that as a unit provided care to 14% of the total number of pituitary patients nationally.
Miss Grieve was clinical lead for neurosurgery from 2007-2013, managing the department of neurosurgery at that time comprising of 18 surgeons, including 14 neurosurgeons, two orthopaedic surgeons and two ENT surgeons. During her tenure, she oversaw the amalgamation of neurosurgical services for North Central London (then based at the NHNN and Royal Free Hospitals) into a single service at the NHNN. She also oversaw the opening of the first nationally dedicated brain tumour ward, Molly Lane Fox Brain Tumour Unit; and the provision of a single site pituitary and skull base neurosurgical service for North London at Queen Square.
She was elected a member of council of the Society of British Neurosurgeons in 2018. She is also an international member of the Congress of Neurological Surgeons and a member of the Society of University Neurosurgeons.
Pituitary, parasellar pathology, gamma knife radiosurgery, neuro-oncology, general neurosurgery
1. ANGPTL6 genetic variants are an important cause of familial intracranial aneurysms I Hostettler, B O'Callaghan, e Bugiardini, E O'Connor, J Vandrovcova, I Davagnanam, S Bonner, D Walsh, D Bulters, N Kitchen, M Brown, J Grieve, D Werring, H Houlden. Neurology (in press) 2020
2. CSF rhinorrhoea after endonasal intervention to the anterior skull base (CRANIAL): Proposal for a prospective multicentre observational cohort study. DZ Han, S Bandyopadhyay, V Patel, B Shroeder, I Cabrilo, D Choi, S Cudlip, N Donnelly, N Dorward, D Fountain, J Grieve, J Halliday, A Kolias, R Mannion, A O'Donnell, n Phillips, R Piper, B Ramachandran, T Santarius, P Sayl, R Sharma, G Solomou, J Tysome, H Marcus. British Journal of Neurosurgery (in press) 2020
3. Can Gamma Knife Radiosurgery for brain arteriovenous malformations be planned on triple Magnetic Resonance Angiography (triple-MRA)? A Rojas-Villabona, M Sokolska, T Solbach, J Grieve, M Rega, F Torrealdea, F Pizzini, E de Vita, Y Suzuki, M Van Osch, E Blondetti, K Shmuell, D Atkinson, M Murphy, I Paddick, X Golay, N Kitchen, HR Jager. British Journal of Neurosurgery (in press) 2020
4. Assessment of the Subarachnoid Hemorrhage International Trialists (SAHIT) Models for Dichotomized Long-Term Functional Outcome Prediction After Aneurysmal Subarachnoid Hemorrhage in a United Kingdom Multicenter Cohort Study. Hostettler IC, Pavlou M, Ambler G, Alg VS, Bonner S, Walsh DC, Bulters D, Kitchen N, Brown MM, Grieve J, Houlden H, Werring DJ. Neurosurgery. 2020 Jul 25:nyaa299. doi: 10.1093/neuros/nyaa299. Online ahead of print. PMID: 327107671.
5. Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors. Marques P, Caimari F, Hernández-Ramírez LC, Collier D, Iacovazzo D, Ronaldson A, Magid K, Lim CT, Stals K, Ellard S, Grossman AB, Korbonits M; FIPA Consortium. J Clin Endocrinol Metab. 2020 Jun 1;105(6):e2247-60. doi: 10.1210/clinem/dgaa040. PMID: 31996917
6. Rathke's cleft cysts following transsphenoidal surgery: long-term outcomes and development of an optimal follow-up strategy. Marcus HJ, Borg A, Hussein Z, Jaunmuktane Z, Baldeweg SE, Grieve J, Dorward NL. Acta Neurochir (Wien). 2020 Apr;162(4):853-861. doi: 10.1007/s00701-020-04237-5. Epub 2020 Jan 25. PMID: 31982988
7. Haptoglobin genotype and outcome after aneurysmal subarachnoid haemorrhage. Morton MJ, Hostettler IC, Kazmi N, Alg VS, Bonner S, Brown MM, Durnford A, Gaastra B, Garland P, Grieve J, Kitchen N, Walsh D, Zolnourian A, Houlden H, Gaunt TR, Bulters DO, Werring DJ, Galea I; Genetics and Observational Subarachnoid Haemorrhage (GOSH) Study investigators. J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):305-313. doi: 10.1136/jnnp-2019-321697. Epub 2020 Jan 14. PMID: 31937585
8. Craniopharyngioma in children: trends from a third consecutive single-center cohort study. Marcus HJ, Rasul FT, Hussein Z, Baldeweg SE, Spoudeas HA, Hayward R, Jeelani NUO, Thompson D, Grieve JP, Dorward NL, Aquilina K. J Neurosurg Pediatr. 2019 Dec 20:1-9. doi: 10.3171/2019.10.PEDS19147. Online ahead of print. PMID: 31860822
9. Reducing Intrathecal Baclofen Related Infections: Service Evaluation and Best Practice Guidelines. Balaratnam MS, Donnelly A, Padilla H, Simeoni S, Bahadur S, Keenan L, Lee H, Farrell R, Curtis C, Brownstone RM, Murphy M, Grieve J, Shieff C, Nayar M, Pitceathly RDS, Christofi G, Stevenson VL. Neuromodulation. 2019 Dec 12. doi: 10.1111/ner.13071. Online ahead of print. PMID: 31828902
10. Olfactory outcomes after transsphenoidal endonasal surgery. Baudracco I, Ekanayake J, Warner E, Grieve JP, Dorward NL. Br J Neurosurg. 2020 Feb;34(1):35-39. doi: 10.1080/02688697.2019.1680798. Epub 2019 Nov 11. PMID: 31709822
11. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. Marques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Dorward N, Grieve J, Mendoza N, Muquit S, Grossman AB, Balkwill F, Korbonits M. Acta Neuropathol Commun. 2019 Nov 8;7(1):172. doi: 10.1186/s40478-019-0830-3. PMID: 31703742
12. Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness. Marques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Dorward N, Grieve J, Mendoza N, Muquit S, Grossman AB, Balkwill F, Korbonits M. Endocr Relat Cancer. 2019 Dec;26(12):853-865. doi: 10.1530/ERC-19-0327. PMID: 31645017
13. Informed Consent for Patients Undergoing Transsphenoidal Excision of Pituitary Adenoma: Development and Evaluation of a Procedure-Specific Online Educational Resource. Marcus HJ, Jain A, Grieve J, Dorward NL. World Neurosurg. 2018 Oct;118:e933-e937. doi: 10.1016/j.wneu.2018.07.102. Epub 2018 Jul 19. PMID: 30031952
14. Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members' View in an AIP Mutation-Positive Family. Marques P, Barry S, Ronaldson A, Ogilvie A, Storr HL, Goadsby PJ, Powell M, Dang MN, Chahal HS, Evanson J, Kumar AV, Grieve J, Korbonits M. Int J Endocrinol. 2018 Apr 4;2018:8581626. doi: 10.1155/2018/8581626. eCollection 2018. PMID: 29849625
15. Management of incidental aneurysms: comparison of single Centre multi-disciplinary team decision making with the unruptured incidental aneurysm treatment score. Smedley A, Yusupov N, Almousa A, Solbach T, Toma AK, Grieve JP. Br J Neurosurg. 2018 Oct;32(5):536-540. doi: 10.1080/02688697.2018.1468019. Epub 2018 May 15. PMID: 29764206